Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor...

Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanomaKIMMTRAK is the first and only FDA approved therapy for the treatment of...

Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference Immunocore to present at the 40th Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 6 January 2022) Immunocore Holdings Plc (Nasdaq:...

Immunocore to present at upcoming investor conferences PRESS RELEASE Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 27 May 2021) Immunocore (Nasdaq: IMCR), a late-stage...